


JUL 23 2007



INFORMATION DISCLOSURE STATEMENT BY APPLICANT FORM PTO-1449/A (07-06-07) Modified PTO/SB/08				APPLICATION NO.: 09/669,187	ATTY. DOCKET NO.: C1039.70035US00	
				FILING DATE: September 25, 2000	CONFIRMATION NO.: 2999	
				APPLICANT: Krieg et al.		
				GROUP ART UNIT: 1643	EXAMINER: David J. Blanchard	
Sheet 1 of 1						

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/DB/		Press Release, Pfizer Inc., Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer. June 20, 2007. 1 page.	

EXAMINER:

/David Blanchard/


DATE CONSIDERED:

01/31/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]



FORM PTO-1449/A and B (modified PTO/SB/18)				APPLICATION NO.: 09/669,187	ATTY. DOCKET NO.: C1039.70035US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: September 25, 2000	CONFIRMATION NO.: 2999
				APPLICANT: Krieg et al.	
Sheet	1	of	1	GROUP ART UNIT: 1643	EXAMINER: David J. Blanchard

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
/DB/		WO	00/46365	A1	Virginia Commonwealth University	08-10-2000	
/DB/		WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)

EXAMINER: /David Blanchard/	DATE CONSIDERED: 01/29/2008
--------------------------------	-----------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

{NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.}

NOV 6 2007

FORM PTO-1449/A and B (modified PTO/SB/08)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet

1

of

9

APPLICATION NO.:	09/669,187	ATTY. DOCKET NO.:	C1039.70035US00
FILING DATE:	September 25, 2000	CONFIRMATION NO.:	2999
APPLICANT: Krieg et al.			
GROUP ART UNIT:	1643	EXAMINER:	David J. Blanchard

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/DB/	5,087,617			Smith	02-11-1992
	5,877,309			McKay et al.	03-02-1999
	5,955,059			Gilchrest et al.	09-21-1999
	5,997,858			Tovey et al.	12-07-1999
	6,426,334	B1		Agrawal et al.	07-30-2002
	6,514,948	B1		Raz et al.	02-04-2003
	6,534,062	B1		Raz et al.	03-18-2003
	6,562,798	B1		Schwartz	05-13-2003
	6,589,940	B1		Raz et al.	07-08-2003
	6,610,308	B1		Haensler	08-26-2003
	6,835,395	B1		Semple et al.	12-28-2004
	6,893,821	B2		Raz et al.	05-17-2005
	2001-0036462	A1		Fong et al.	11-01-2001
	2002-0065236	A1		Yew et al.	05-30-2002
	2003-0119773	A1		Raz et al.	06-26-2003
	2003-0125279	A1		Junghans et al.	07-03-2003
	2003-0125284	A1		Raz et al.	07-03-2003
	2003-0138413	A1		Vicari et al.	07-24-2003
	2003-0143213	A1		Raz et al.	07-31-2003
	2003-0147870	A1		Raz et al.	08-07-2003
	2003-0176373	A1		Raz et al.	09-18-2003
	2004-0006034	A1		Raz et al.	01-08-2004
	2004-0038922	A1		Haensler et al.	02-26-2004
	2004-0092468	A1		Schwartz et al.	05-13-2004
	2005-0209184	A1		Klinman et al.	09-22-2005
	2005-0214355	A1		Klinman et al.	09-29-2005
/DB/	2005-0282763	A1		Hedley	12-22-2005

EXAMINER:	DATE CONSIDERED:
/David Blanchard/	01/29/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Enclose copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet	2	of	9	GROUP ART UNIT: 1643	EXAMINER: David J. Blanchard
-------	---	----	---	----------------------	------------------------------

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
/DB/	WO	95/17507	A1	Biognostik Gesellschaft Für	06-29-1995		
	WO	96/02560	A1	University of North Carolina at Chapel	02-01-1996		
	WO	98/32462	A1	Wagner et al.	07-30-1998		
	WO	98/49288	A1	Hybridon Inc.	11-05-1998		
	WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Y-Abstract	
	WO	00/45849	A2	Genzyme Corporation	08-10-2000		
	WO	00/61151	A2	The Government of the United States of	10-19-2000		
	WO	00/67787	A2	The Immune Response Corporation	11-16-2000		
	WO	01/45750	A1	Regents of the University of California	06-28-2001		
	WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Y-Abstract	
	WO	03/020889	A2	3M Innovative Properties Company	03-13-2003		
↓	WO	03/025119	A2	Medarex Inc.	03-27-2003		
	WO	03/043572	A2	3M Innovative Properties Company	05-30-2003		
/DB/	WO	03/045428	A2	Medigene Aktiengesellschaft	06-05-2003	Y-Abstract	

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/DB/	[No Author Listed] CpG 7909: PF 3512676, PF-3512676. Drugs R D. 2006;7(5):312-6.		
	AGRAWAL et al., Chapter 19: Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals. 1998: 525-43.		
	ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.		
	ASKEW et al., CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol. 2000 Dec 15;165(12):6889-95.		
	BALLAS et al., Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001 Nov 1;167(9):4878-86.		
	BAUER et al., DNA activates human immune cells through a CpG sequence-dependent manner. Immunology. 1999 Aug;97(4):699-705.		
↓	BAYEVER et al., Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev. 1993 Winter;3(4):383-90.		
/DB/	BOGGS et al., Characterization and modulation of immune stimulation by modified		

EXAMINER: /David Blanchard/	DATE CONSIDERED: 01/29/2008
--------------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Enclose copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet

3

of

9

APPLICATION NO.:	09/669,187	ATTY. DOCKET NO.:	C1039.7003SUS00
FILING DATE:	September 25, 2000	CONFIRMATION NO.:	2999
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1643	EXAMINER:	David J. Blanchard

	oligonucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):461-71.	
/DB/	CARPENTIER et al., Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. <i>Cancer Res.</i> 1999 Nov 1;59(21):5429-32.	
	CARPENTIER et al., Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. <i>Clin Cancer Res.</i> 2000 Jun;6(6):2469-73.	
	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. <i>Clin Immunol Immunopathol.</i> 1997 Aug;84(2):185-93.	
	CHU et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>J Exp Med.</i> 1997 Nov 17;186(10):1623-31.	
	COHEN, Selective anti-gene therapy for cancer: principles and prospects. <i>Tohoku J Exp Med.</i> 1992 Oct;168(2):351-9.	
	DAVILA et al., Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. <i>J Immunol.</i> 2000 Jul 1;165(1):539-47.	
	DAVIS, Use of CpG DNA for enhancing specific immune responses. <i>Curr Top Microbiol Immunol.</i> 2000;247:171-83.	
	DECKER et al., Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. <i>Blood.</i> 2000 Feb 1;95(3):999-1006.	
	DELEVOYE et al., Eurotech Data: <i>Cancer Chemotherapy</i> , Jan 2000:1-98. Report.	
	GROSSMANN et al., Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. <i>J Immunother.</i> 2001 May-Jun;24(3):237-41.	
	HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. <i>Gene Ther.</i> 1999 May;6(5):893-903.	
	HEEG et al., CpG DNA as a Th1 trigger. <i>Int Arch Allergy Immunol.</i> 2000 Feb;121(2):87-97.	
	HIGAKI et al., Mechanisms involved in the inhibition of growth of a human B lymphoma cell line, B104, by anti-MHC class II antibodies. <i>Immunol Cell Biol.</i> 1994 Jun;72(3):205-14.	
	HINKULA et al., Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. <i>J Virol.</i> 1997 Jul;71(7):5528-39.	
	HOPKIN et al., Curbing the CpGs of Bacterial and Viral DNA. <i>BioMedNet.</i> 1999 Jun 25; Issue 57.	
	IHO et al., Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro. <i>J Immunol.</i> 1999 Oct 1;163(7):3642-52.	
	JAHRSDORFER et al., CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. <i>J Leukoc Biol.</i> 2001 Jan;69(1):81-8.	
	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. <i>Drug News Perspect.</i> 2000 Jun;13(5):289-96.	
▼	KLINMAN et al., Immunotherapeutic uses of CpG oligodeoxynucleotides. <i>Nat Rev Immunol.</i> 2004 Apr;4(4):249-58.	
/DB/	KLINMAN et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. <i>J Immunol.</i>	

EXAMINER:

/David Blanchard/

DATE CONSIDERED:

01/29/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Enclose copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 09/669,187	ATTY. DOCKET NO.: C1039.70035US00
		FILING DATE: September 25, 2000	CONFIRMATION NO.: 2999
		APPLICANT: Krieg et al.	
		GROUP ART UNIT: 1643	EXAMINER: David J. Blanchard
Sheet	4	of	9

	1997 Apr 15;158(8):3635-9.	
/DB/	KLINMAN et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83.	
	KOVARIK et al., CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol. 1999 Feb 1;162(3):1611-7.	
	KRANZER et al. CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology. 2000 Feb;99(2):170-8.	
	KRIEG et al., Immune effects and therapeutic applications of CpG motifs in bacterial DNA. Immunopharmacology. 2000 Jul 25;48(3):303-5.	
	KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
	KRIEG, CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol. 1995 Nov;15(6):284-92.	
	KRIEG et al., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546-9.	
	KRIEG et al., The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998 Jan;6(1):23-7.	
	KRIEG, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med. 1996 Aug;128(2):128-33.	
	KRIEG et al., CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-60.	
	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct;21(10):521-6.	
	KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. In: Antisense Research and Application. Crooke, Ed. 1998:243-62.	
	KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal <i>L. monocytogenes</i> challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996:116.	
	KRIEG et al., Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 Feb;3(1):15-24.	
	KRIEG et al., Chapter 7: CpG oligonucleotides as immune adjuvants. Ernst Schering Research Found Workshop 2001; 30:105-18.	
	KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000 Nov 8;19(6):618-22.	
▼	KRIEG et al., Chapter 17:Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
/DB/	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides.	

EXAMINER:	/David Blanchard/	DATE CONSIDERED:
		01/29/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet	5	of	9	GROUP ART UNIT: 1643	EXAMINER: David J. Blanchard
-------	---	----	---	----------------------	------------------------------

/DB/	Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.
	KRIEG, The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb;12(1):35-43.
	KRIEG et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. 1999 Nov;84(2):113-20.
	KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.
	KRIEG et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 1;161(5):2428-34.
	KRIEG et al., CpG DNA: a novel immunomodulator. Trends Microbiol. 1999 Feb;7(2):64-5.
	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):97-105.
	KRIEG et al., Infection. In: McGraw Hill Book. 1996:242-3.
	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.
	KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.
	KRIEG, Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.
	KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71.
	KRIEG et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1048-52.
	KRIEG et al., Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999 Jan-Feb;1(1):56-63.
	KRIEG et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation. J Immunol. 1989 Oct 15;143(8):2448-51.
	KRIEG et al., P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides. 2003;13(6):491-9.
	KRIEG et al., How to exclude immunostimulatory and other nonantisense effects of antisense oligonucleotides. Manual of Antisense. 1999:79-89.
	KRIEG et al., Unmethylated CpG DNA protects mice from lethal listeria monocytogenes challenge. Vaccines. 1997; 97:77-9.
	KRIEG et al., Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52.
	KRIEG et al., Rescue of B cells from apoptosis by immune stimulatory CpG DNA. Springer Semin Immunopathol. 2000;22(1-2):55-61.
↓	KRIEG et al., Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007 Jul;4(3):289-94.
/DB/	KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol.

EXAMINER:	/David Blanchard/	DATE CONSIDERED:	01/29/2008
-----------	-------------------	------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet

6

of

9

APPLICATION NO.:	09/669,187	ATTY. DOCKET NO.:	C1039.70035US00
FILING DATE:	September 25, 2000	CONFIRMATION NO.:	2999
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1643		EXAMINER: David J. Blanchard

1992 Jul;14(5):773-82.

/DB/ KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation. *Jpn J Cancer Res.* 1992 Nov;83(11):1128-31.KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. *Microbiol Immunol.* 1989;33(11):929-40.LEE et al., Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations. *Immunology.* 1998 Jul;94(3):285-9.LEITNER et al., Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants. *Curr Pharm Des.* 2001 Nov;7(16):1641-67.LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. *Eur J Immunol.* 1997 Sep;27(9):2340-4.LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. *Eur J Immunol.* 1997 Dec;27(12):3420-6.LIPFORD et al., Bacterial DNA as immune cell activator. *Trends Microbiol.* 1998 Dec;6(12):496-500.LIU et al., Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. *Blood.* 1998 Nov 15;92(10):3730-6.LOKE et al., Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis. *Curr Top Microbiol Immunol.* 1988;141:282-9.MACFARLANE et al., Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step. *Immunology.* 1997 Aug;91(4):586-93.MALTESE et al., Sequence context of antisense RelA/NF-kappa B phosphorothioates determines specificity. *Nucleic Acids Res.* 1995 Apr 11;23(7):1146-51.MANEGOLD et al., Addition of PF-3512676 (CpG 7909) to a taxane/platinum regimen for first-line treatment of unresectable non-small cell lung cancer (NSCLC) improves objective response—Phase II clinical trial. *Pfizer Poster.* 2005. Abstract 1131.MANZEL et al., CpG-oligodeoxynucleotide-resistant variant of WEHI 231 cells. *J Leukoc Biol.* 1999 Nov;66(5):817-21.MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. *Int Immunol.* 1999 Jul;11(7):1111-8.McCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. *J Immunol.* 1998 Nov 1;161(9):4463-6.McCLUSKIE et al., CpG DNA as mucosal adjuvant. *Vaccine.* 2000;18: 231-7.McCLUSKIE et al., Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. *Vaccine.* 2000 Oct 15;19(4-5):413-22./DB/ McCLUSKIE et al., CpG DNA is an effective oral adjuvant to protein antigens in mice. *Vaccine.*

EXAMINER: /David Blanchard/	DATE CONSIDERED: 01/29/2008
--------------------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet 7 of 9

APPLICATION NO.:	09/669,187	ATTY. DOCKET NO.:	C1039.70035US00
FILING DATE:	September 25, 2000	CONFIRMATION NO.:	2999
APPLICANT:	Krieg et al.		
GROUP ART UNIT:	1643		EXAMINER: David J. Blanchard

	2000 Nov 22;19(7-8):950-7.	
/DB/	OCHIAI et al., Studies on lymphocyte subsets of regional lymph nodes after endoscopic injection of biological response modifiers in gastric cancer patients. <i>Int J Immunotherapy</i> . 1986;11(4):259-65. Abstract Only.	
	PAUL et al., Technology evaluation: CpG-7909, Coley. <i>Curr Opin Mol Ther</i> . 2003 Oct;5(5):553-9. Abstract Only.	
	PAYETTE et al., History of vaccines and positioning of current trends. <i>Curr Drug Targets Infect Disord</i> . 2001 Nov;1(3):241-7.	
	PERLAKY et al., Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. <i>Anticancer Drug Des</i> . 1993 Feb;8(1):3-14.	
	PISETSKY et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. <i>Mol Biol Rep</i> . 1993 Oct;18(3):217-21.	
	PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. <i>Immunol Res</i> . 1999;19(1):35-46.	
	POLANCZYK et al., Immunostimulatory effects of DNA and CpG motifs. <i>Cent Eur J of Immunol</i> . 2000;25(3):160-6.	
	RATAJCZAK et al., In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. <i>Proc Natl Acad Sci U S A</i> . 1992 Dec 15;89(24):11823-7.	
	SATOH et al., The study of mechanisms in CpG oligodeoxynucleotides-induced aggravation in murine allergic contact dermatitis to 2,4-dinitrofluorobenzene. <i>Fukushima Igaku Zasshi</i> . 2002;52(3):237-50. Abstract Only.	
	SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. <i>J Immunol</i> . 1999 Jul 1;163(1):224-31.	
	SESTER et al., Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. <i>J Immunol</i> . 2000 Oct 15;165(8):4165-73.	
	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. <i>J Interferon Cytokine Res</i> . 1996 Oct;16(10):799-803.	
	SPARWASSER et al., Bacterial DNA causes septic shock. <i>Nature</i> . 1997 Mar 27;386(6623):336-7.	
	SPARWASSER et al., Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. <i>Eur J Immunol</i> . 1998 Jun;28(6):2045-54.	
	SPARWASSER et al., Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. <i>J Immunol</i> . 1999 Feb 15;162(4):2368-74.	
	SPARWASSER et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol</i> . 1997 Jul;27(7):1671-9.	
	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. <i>Antisense Res Dev</i> . 1994 Summer;4(2):67-9.	
↓	STEIN et al., Non-antisense effects of oligodeoxynucleotides. <i>Antisense Technology</i> . 1997; ch11: 241-64.	
/DB/	SUN et al. Type I interferon-mediated stimulation of T cells by CpG DNA. <i>J Exp Med</i> . 1998 Dec	

EXAMINER:	/David Blanchard/	DATE CONSIDERED:	01/29/2008
-----------	-------------------	------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet	8	of	9	APPLICATION NO.: 09/669,187	ATTY. DOCKET NO.: C1039.70035US00
				FILING DATE: September 25, 2000	CONFIRMATION NO.: 2999
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1643	EXAMINER: David J. Blanchard

	21;188(12):2335-42.	
/DB/	SUN et al. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. Springer Semin Immunopathol. 2000;22(1-2):77-84.	
	TAKATSUKI et al., Interleukin 6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment. Cancer Res. 1990 May 15;50(10):2885-90.	
	TANAKA et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion. J Exp Med. 1992 Feb 1;175(2):597-607.	
	THREADGILL et al., Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. Vaccine. 1998 Jan;16(1):76-82.	
	TOKUNAGA et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. Jpn J Cancer Res. 1988 Jun;79(6):682-6.	
	TOKUNAGA et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells. Microbiol Immunol. 1992;36(1):55-66.	
	TOKUNAGA, Response of the organism to DNA – With a focus on immunostimulatory DNA. Kansen Ensho Meneki. 2001 Autumn; 31(3): 1-12. Japanese.	
	VERTHELYI et al., Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol. 2001 Feb 15;166(4):2372-7.	
	WARREN et al., APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol. 2000 Dec 1;165(11):6244-51.	
	WEERATNA et al., CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 2000 Mar 6;18(17):1755-62.	
	WEINER et al., Immunostimulatory CpG oligodeoxynucleotide is effective as an adjuvant in inducing production of anti-idiotype antibody and is synergistic with GMCSF. Blood. 1996 Nov 15;88(10):Suppl. 1 pt. 1. Abstract #348.	
	WHITMORE et al., Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Canc Immun Immunother. 2001;50:503-14.	
	WOOLDRIDGE et al., Select unmethylated CpG oligodeoxynucleotide improve antibody dependent cellular cytotoxicity in vitro and in vivo. Proc Am Assoc Cancer Res. 1996 Mar;37(3253):477.	
	WOOLDRIDGE et al., Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15;89(8):2994-8.	
↓	YAMAMOTO et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. Microbiol Immunol. 1994;38(10):831-6.	
/DB/	YAMAMOTO et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol. 1992 Jun 15;148(12):4072-6.	

EXAMINER:	/David Blanchard/	DATE CONSIDERED:	01/29/2008
-----------	-------------------	------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 09/669,187	ATTY. DOCKET NO.: C1039.7003SUS00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: September 25, 2000	CONFIRMATION NO.: 2999
				APPLICANT: Krieg et al.	
Sheet	9	of	9	GROUP ART UNIT: 1643	EXAMINER: David J. Blanchard

/DB/	YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from <i>Mycobacterium bovis</i> BCG] <i>Kekkaku</i> . 1994 Sep;69(9):571-4. Japanese.	
	YAMAMOTO et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. <i>Antisense Res Dev</i> . 1994 Summer;4(2):119-22.	
	YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. <i>Jpn J Cancer Res</i> . 1994 Aug;85(8):775-9.	
	YAMAMOTO et al., Oligodeoxyribonucleotides with 5'-ACGT-3' or 5'-TCGA-3' sequence induce production of interferons. <i>Curr Top Microbiol Immunol</i> . 2000;247:23-39.	
	YAMAMOTO et al., Cytokine production inducing action of oligo DNA. <i>Rinsho Meneki</i> . 1997;29(9):1178-1184. Japanese.	
	YI et al. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. <i>J Immunol</i> . 1998 Nov 1;161(9):4493-7.	
	YI et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. <i>J Immunol</i> . 1996 Dec 15;157(12):5394-402.	
	YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. <i>J Immunol</i> . 1996 Jan 15;156(2):558-64.	
↓	YI et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. <i>J Immunol</i> . 1998 Jun 15;160(12):5898-906.	
/DB/	ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. <i>Antisense Nucleic Acid Drug Dev</i> . 1997 Oct;7(5):495-502.	

EXAMINER:	/David Blanchard/	DATE CONSIDERED:	01/29/2008
-----------	-------------------	------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to Applicant.

copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	/David Blanchard/	DATE CONSIDERED:	01/29/2008
-----------	-------------------	------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to Applicant.

Index of Claims

Application/Control No.

09/669,187

Examiner

David J. Blanchard

Applicant(s)/Patent under Reexamination

KRIEG ET AL.

Art Unit

1643

✓	Rejected
=	Allowed

-	(Through numeral) Cancelled
÷	Restricted

N	Non-Elected
I	Interference

A	Appeal
O	Objected

Claim	Date
Final	
Original	1/29/08
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	

Claim	Date
Final	
Original	1/29/08
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

Claim	Date
Final	
Original	1/29/08
101	
102	
103	
104	
105	
106	
107	
108	
109	
110	
111	
112	
113	
114	
115	
116	
117	
118	
119	
120	
121	
122	
123	
124	
125	
126	
127	
128	
129	
130	
131	
132	
133	
134	
135	
136	
137	
138	
139	
140	
141	
142	
143	
144	
145	
146	
147	
148	
149	
150	